research reports and media, page-2506

My estimates are it should be an 8 figure R&D rebate. We should find out very soon.

Another thing to factor in is if there are no safety concerns observed for the adrenal issues the FDA noted last year then PAR can request having this monitoring removed from PARA 003, thus reducing the costs. Also, PARA 003 should also cost less than PARA 002 since all the systems will already be in place by then. I assume when PAR does a cap raise they will present it as raising to fund NDA submission and commercialisation, while also including a condition that some funds may be used to complete PARA 003 IMO.